Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 62, Issue 23, Pages 10757-10782Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b01227
Keywords
-
Categories
Funding
- SFB autophagy
- German cancer network DKTK
- SGC, a registered charity [1097737]
- AbbVie
- Bayer Pharma AG
- Boehringer Ingelheim
- Canada Foundation for Innovation
- Eshelman Institute for InnovationGenome Canada through Ontario Genomics Institute [OGI-055]
- Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD Grant] [115766]
- Janssen
- Merck KGaA
- MSD
- Novartis Pharma AG
- Ontario Ministry of Research, Innovation and Science (MRIS)
- Pfizer
- Sao Paulo Research Foundation-FAPESP
- Takeda
- Wellcome Trust
- DFG [SFB1177]
- German Cancer Consortium
- European Union's Horizon 2020 research and innovation program [730872]
Ask authors/readers for more resources
p38 mitogen-activated protein kinases are key mediators of environmental stress response and are promising targets for treatment of inflammatory diseases and cancer. Numerous efforts have led to the discovery of several potent inhibitors; however, so far no highly selective type-II inhibitors have been reported. We previously identified VPC-00628 as a potent and selective type-II inhibitor of p38 alpha/beta with few off-targets. Here we analyzed the chemical building blocks of VPC-00628 that played a key role in achieving potency and selectivity through targeting an inactive state of the kinases induced by a unique folded P-loop conformation. Using a rapid, systematic combinatorial synthetic approach, we identified compound 93 (SR-318) with excellent potency and selectivity for p38 alpha/beta, which potently inhibited the TNF-alpha release in whole blood. SR-318 therefore presents a potent and selective type-II inhibitor of p38 alpha/beta that can be used as a chemical probe for targeting this particular inactive state of these two p38 isoforms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available